Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Life Science VC (Venture Capital) Funds in Switzerland in February 2025

Last updated: Feb 2025 A list of 50 VC (Venture Capital) funds that invest in Life science startups based in Switzerland. We rank investors based on the number of investments they made in Life science companies from Switzerland. We update this investor list every month.

Top 50 Life Science VC (Venture Capital) Funds in Switzerland in February 2025

Investor	Life Science Switzerland investments
Zürcher Kantonal Bank	5
Eclosion SA	4
Foundation for Innovation and Technology (FIT)	3
Omega Funds	2
Verve Ventures	2
FAST — by GETTYLAB	2
Sunstone Life Science Ventures	2
EQT Life Sciences	2
Kinled Holding	2
VINCI CAPITAL	2
SOSV	2
BlueOcean Ventures	2
Versant Ventures	2
BioMedPartners	2
Lichtsteiner Foundation	2
Rheingau Founders	2
HTGF \| High-Tech Gruenderfonds	2
Fongit Seed Invest	2
Primal Capital	1
VI Partners	1
Gaingels	1
UZH Life Sciences Fund	1
The Helm	1
Pfizer Venture Investments	1
Bruker	1
Indaco Venture Partners	1
Think.Health	1
Novartis Venture Fund	1
HBM Healthcare Investments AG	1
Technology Fund	1
TiVentures	1
SICTIC	1
Acequia Capital (AceCap)	1
Primal Capital	1
Boehringer Ingelheim Venture Fund	1
M Ventures	1
Idinvest Partners	1
Esperante Ventures	1
University of Zurich	1
EFI Lake Geneva Ventures	1
Privilège Ventures	1
Recipharm Venture Fund	1
Amboy Street Ventures	1
Heritage Capital	1
Medicxi	1
Renaissance	1
Rhia Ventures	1
White Loop Capital	1
RH Capital	1
S2S Ventures	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Series A, Funding Round
Switzerland, Japan, Spain

Portfolio highlights

Somagenetix — Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses. Somagenetix's mission is to use genetically modified phagocytes to treat patients suffering from immunodeficiency, neurodegeneration, and cancer with brain metastases.
Retinai — RetinAI optimises and simplifies clinics, research and pharmaceutical workflows to improve healthcare. To achieve this goal, the company builds tools to collect, analyze and organize health data, empowering healthcare professionals and patients with automatic image and data analysis supported by advanced machine learning. RetinAI has proprietarytechnology that provides unforeseen image quality enhancement, as well as automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies and device manufacturers at similar level of performance as a human would produce.
Lymphatica Medtech — Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle.

Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up

Investment focus

Biotechnology, Pharmaceutical, Health Care
Seed, Series C, Funding Round
Switzerland

Portfolio highlights

KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases

The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.

Investment focus

Health Care, Biotechnology, Software
Debt Financing, Grant, Seed
Switzerland, France

Portfolio highlights

Aspivix — ASPIVIX is developing a new generation of medical devices that make gynecological procedures gentler and safer for women and gynecologists. The first device, CAREVIX, is designed to prevent cervix bleeding using a suction technology to replace traumatic tenaculum (forceps).
Xemperia — Xemperia provides diagnostic solutions that helps to detect breast cancer and early diagnosis of relapses.
Ex Nunc Intelligence — Ex Nunc Intelligence provides professionals with thorough summaries of legal information, credible responses to legal issues, and automated legal document preparation features.

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
Alleviant Medical — Interventional therapy for congestive heart failure
Aviceda Therapeutics — Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases. The company focuses on the next generation of immunomodulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. A combination ofcutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation.Aviceda uses its cell-based high-throughput screening (HTS) platform to rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. . The company's products are for eye diseases, fibrosis, neurology, and oncology, for eye diseases like AVD-104, AVD-302, AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma respectively AVD-601, AVD-701 and AVD-801 for oncology, neurology, and fibrosis respectively.

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Series B
Switzerland, France, Germany

Portfolio highlights

tozero — Truly bringing lithium-ion battery waste tozero by recovering all critical matierlas, like lithium, nickel, cobalt, manganese, and graphite.
Metafuels — Our breakthrough sustainable aviation fuel (SAF) technology, aerobrew™, will make affordable net-zero aviation a reality. The technology is innovative, highly scaleable and able to tap into future global renewable energy systems efficiently. Starting from renewable feedstocks including green hydrogen, driven by renewable electricity, andsustainably sourced CO2, for example from direct air capture, aerobrew™ provides an efficient route to large-scale production of e-kerosene, overcoming the scale up challenges and high costs of alternative e-fuels technologies. aerobrew™ is also compatible with the biogenic route whereby the carbon required for the process is derived from renewable and sustainable cellulosic biomass which, does not compete with the food chain (wood, miscanthus, etc.). With a high carbon conversion, high selectivity and a high overall SAF yield, aerobrew™ leads to attractive production economics and cost leadership. With a rapidly growing demand for SAF, aerobrew™ stands to contribute significantly to the decarbonisation of global aviation and to support the achievement of net zero 2050 targets.
Orakl Oncology — Cultivated with love by the Orakl team.

Backing engineers building awe, wonder, speed.

Investment focus

Software, Biotechnology, Health Care
Pre-Seed, Seed, Funding Round
United States, United Kingdom, France

Portfolio highlights

Yakoa — Harness AI to detect and address infringements, effortlessly. Eliminate manual searches, experience ecosystem-wide forensics and Proactively screen violations.
Modelwise — Automated functional safety analysis via drag & drop. Seamless Integration. Faster Analyses. Zero Defects. More Savings.
Fluent Metal — Fluent Metal is a company that makes metal 3D printing economical, efficient, and safe.

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Series B, Series A
Denmark, Sweden, Switzerland

Portfolio highlights

Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.

Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

XyloCor Therapeutics — XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patientswith refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively.
Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
Tenpoint Therapeutics — Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye.

Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.

Investment focus

Biotechnology, Health Care, Financial Services
Seed, Funding Round, Series A
United Kingdom, United States, Switzerland

Portfolio highlights

Xapien — Xapien delivers automated insight reports on companies and individuals in minutes, so you can make informed business decisions quickly and with confidence.
OneTrust — OneTrust is a provider of privacy management and marketing compliance technology that helps organizations comply with global regulations. It automates privacy impact assessments and data inventory mapping, enforces risk remediation actions, and triggers recurring audits for continuous compliance monitoring across customer, employee, and vendor datatransfers. Its web-based software can be accessed on any device and provides a single place for a private office to collaborate with business groups, vendors, and trusted advisors managing privacy risks. The result is the ability to demonstrate privacy by design and ongoing compliance with policies, data privacy laws (GDPR, BCR, Privacy Shield), and other privacy frameworks (HITECH, ISO, GAPP, APEC).The company was founded in 2016 and is headquartered in Atlanta, Georgia.
Connect Earth — Connect Earth is an environmental data company that builds the infrastructure for climate-conscious products by aggregating and standardising environmental data and making it available through developer-first toolkits. The core product is an API solution that calculates the carbon impact of spend-based financial transactions of consumers and companies.

Vinci Capital is a leading Swiss private equity firm with over MCHF 200 under management. Since 1998 they have provided equity to over 30 Swiss technology and industrial companies to finance innovation, growth and succession-buyouts.Their investment team capitalizes on 40 years of cumulated experience in private equity and a solid operationalbackground in growth, turn-around, consolidation, IPOs and M&A situations.

Investment focus

Medical, Health Care, Biotechnology
Series A, Series B, Funding Round
Switzerland, Germany

Portfolio highlights

Anergis — Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland.
SENSIMED — Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.
Beqom — beqom is a Total Compensation Management Software Solution focused exclusively on managing compensation & performance for HR & Sales.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.

Investment focus

Health Care, Medical, Biotechnology
Series A, Seed, Series B
Switzerland, India, France

Portfolio highlights

nPloy — Simply set your filters and get matched with your dream job! Let top employers apply for you & connect with them via chat or a video call.
CyanoGuard AG — Our award-winning cyanide testing and optimizing solution is ideal for the mining, food, and medical field. It's easy to use, digital and offers real-time data.
99RetailStreet — 99RetailStreet is an eCommerce Cloudplatform for the unorganized Retail business in the developing countries. Our ecosystem targets Retailers, Distributors, and Manufacturers. 99RetailStreet provides POS solutions to Retailers, Real-Time Analytics to Manufacturers and Distributors

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Switzerland, Canada

Portfolio highlights

Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
Helicore Biopharma — Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.
Light Horse Therapeutics — Light Horse Therapeutics is the gene editing applied to small-molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that are critical in disease biology. Our initial focus addresseshigh-value, historically challenging oncology targets with the opportunity to apply the technology to other therapeutic areas in the future.

BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Switzerland, Germany, France

Portfolio highlights

ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
TOLREMO therapeutics — TOLREMO therapeutics is striving to prevent the development of cancer therapy resistance through its proprietary drug discovery and development platform. Learn more about us.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.

Investment focus

Medical, Health Care, Biotechnology
Seed, Series A
Switzerland

Portfolio highlights

Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
Testmate Health — 2 in 1 urine test with immediate results for Chlamydia trachomatis and Neisseria gonorrhoeae. Results within minutes & 100% anonymous.
Limula — Limula provides a unique platform technology enabling scale out of cell therapy production. By bringing manufacturing closer to the patients, our solution will broaden access to these highly personalised treatments. Our patented solution is composed of an automation unit and single use kits, allowing healthcare providers to safely manufacture CGTin a decentralized manner. We support companies at all stages of the cell therapy life cycle, from R&D to routine production.

Rheingau Founders is a Berlin&Munich based Venture Capital firm active since 2011. Focusing on pre-seed to Series A investments in Europe, predominantly B2B in the fields of Marketplaces, Software as a Service, InsurTech, and eHealth. Rheingau targets start-ups that have the potential to sustainably disrupt existing processes and value chains.Besides the financial investment, we offer strategic support through the mentorship of our partners.

Investment focus

Software, E-Commerce, Internet
Seed, Series A, Pre-Seed
Germany, United States, Poland

Portfolio highlights

MoleQlar — MoleQlar is a data and research-driven longevity company. It provides valuable information and offers consumers lab-tested nutritional supplements. The company focuses on functional medicine with optimized nutrition. Their product range includes Uthever NMN, Resveratrol, Betaine, Carnosine, and more. These products are aimed at lowering biologicalage and promoting health and longevity. MoleQlar also offers health tracking services. The company is certified in Germany and delivers its products EU-wide, including Switzerland.
Qualifyze — Qualifyze (former ChemSquare) was founded out of the Technical University of Darmstadt in September 2017. Today, we are based in Frankfurt am Main, the heart of Germany’s pharmaceutical cluster, where the leading life science companies are based. Our team consists of 16 people with diverse backgrounds and areas of expertise in business,engineering, and technology as well as several strategic partners from the pharma, food and cosmetics industry.
Akhetonics — Creating the first all-optical RISC Processor

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

Pagent — Pagent develops AI systems.
AUDAVIS — AUDAVIS is developing the most innovative approach that will revolutionize auditing. With data-driven full automation by AUDAVIS and a new AI-based approach, every financial statement becomes a breeze with unprecedented efficiency.
Lindis Blood Care — Lindis Blood Care´s mission is to optimise the outcome of cancer surgeries by developing a Medical Device to remove cancer cells from blood during cancer surgeries to enable Autologous Blood Transfusion.

Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.

Investment focus

Health Care, Medical, Biotechnology
Seed, Series A, Series B
Switzerland

Portfolio highlights

EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.

Primal Capital is an early stage and growth investor in Web3 and emerging technology companies. Our current portfolio consists of 50+ investments in Web3 & blockchain applications focused on consumer and enterprise adoption.

Investment focus

Blockchain, Information Technology, Artificial Intelligence
Seed, Pre-Seed, Series A
United States, United Kingdom, Switzerland

Portfolio highlights

Agents World — Agents World operates as an web3 AI firm.
Fountain — Fountain operates in the finance industry, providing a wallet platform specifically designed for teams. The platform allows users to create permission-controlled wallets in a matter of seconds, offering a centralized location for managing all transactions and treasury. In addition to its wallet services, Fountain also offers a unique way to enjoypodcasts, further diversifying its product offerings. With a team of six, Fountain continues to innovate in the realm of finance and entertainment.
Ooga Booga — Ooga Booga is a liquidity aggregator designed to support the goal of becoming the most capital efficient blockchain.

VI Partners are Venture Capitalists successfully financing outstanding teams and innovations in the Healthcare and Technology space since 20 years.

Investment focus

Health Care, Biotechnology, Medical Device
Series A, Series B, Series C
Switzerland, Germany, United States

Portfolio highlights

Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
LeaseTeq — LeaseTeq bietet Privat- sowie Unternehmenskunden das erste komplett digitale Leasingangebot.
Unique — Try Unique Finance GPT to increase productivity by automating manual workload through AI and ChatGPT solutions.

Gaingels is a leading venture investment syndicate in support of diversity, inclusive of the LGBTQIA+ community and allies in the venture capital space.

Investment focus

Software, Health Care, Artificial Intelligence
Seed, Series A, Series B
United States, Canada, Mexico

Portfolio highlights

1up — 1up is a competitive AI for users to observe and understand everything their competitors are doing. 1up accelerates and automates the competitive experience for teams. 1up enables teams to save hours of manual effort in product, sales, and marketing, understand what their competitors are building and saying, and win competitive deals faster andeasier than ever before.
Holly — Equipping local governments with the tools to streamline hiring, optimize workforce management, and attract top talent. With deep expertise in civic innovation, our team understands the unique challenges facing HR departments and is committed to delivering powerful, data-driven solutions that save time and simplify processes.
Qnovia — Respira Technologies is a platform device and biotechnology company focusing on aerosol science. The company is creating breakthrough aerosol devices and formulations that safely deliver a broad range of pharmaceuticals and nicotine.Respira Technologies' mission is to create novel medical devices of unparalleled efficiency and to advance theprotection of public health with consumer devices through novel innovation, responsible sourcing, draft legislative proposals, transparent product information, and common sense oversight.

The UZH Life Sciences Fund involves two equal partners: the UZH Foundation and the Novartis Venture Fund. It seeks donations from private individuals, foundations and companies for the strategic priorities of the University of Zurich.

Investment focus

Health Care, Biotechnology, Medical Device
Funding Round, Seed, Convertible Note
Switzerland

Portfolio highlights

Occlufit — Occlufit is an occluder device that conforms to complex geometries and provides immediate sealing of cardiovascular defects.
Navignostics — Navignostics combines highly multiplex tumor imaging with advanced data analytics for personalized cancer treatments.
ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.

The Helm is the place to discover, shop, and fund female-identifying entrepreneurs.

Investment focus

Health Care, Communities, E-Commerce
Seed, Funding Round, Series A
United States, Switzerland

Portfolio highlights

Sway — Sway offers regenerative design solutions for plastic pollution using seaweed to create compostable replacements for single-use plastics. The company was co-founded by Julia Marsh, Matt Mayes, and Leland Maschmeyer and is headquartered in San Francisco, California, United States.
Testmate Health — 2 in 1 urine test with immediate results for Chlamydia trachomatis and Neisseria gonorrhoeae. Results within minutes & 100% anonymous.
itselectric — Itselectric partners with city property owners to unlock access to untapped electricity supply while they earn passive income.

Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Switzerland

Portfolio highlights

Enara Bio — Enara Bio is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio focuses on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-relatedDNA sequences.
TRex Bio — TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis.
Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.

Bruker Corporation is a provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis.

Investment focus

Biotechnology, Medical, Health Care
Series A, Funding Round, Seed
United States, Switzerland

Portfolio highlights

KIYATEC — Kiyatec is a functional precision oncology company that measures the response of individual patient live cancer cells with its innovative 3D cell culture technology platform. Kiyatec works with leading biopharmaceutical companies to unlock response dynamics for investigational drug candidates for use in solid tumors.
Haystack Oncology — Haystack Oncology, an oncology company, uses the most recent circulating tumor DNA detection technology to enhance the diagnosis of minimum residual disease and provide superior therapy decision-making information.
Mercy BioAnalytics — We are making early stage cancer 100,000x easier to find using extracellular vesicles found in blood, specific to their parent cells.

VENTURE We invest across all sectors with specific focus on technology and digital The largest independent more About Us Portfolio [...]

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Italy, Switzerland, United States

Portfolio highlights

D-Orbit — End-to-end services for the New Space industry, including platform engineering, launch and deployment, and decommissioning.
MicThera — MicThera focuses on developing microbial-derived therapeutics to provide effective treatments for prostate cancer patients, aiming to find effective solutions for medical companies.
Genespire — Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases.

Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,

Investment focus

Health Care, Biotechnology, Medical Device
Seed, Series A, Series B
Germany, United States, Switzerland

Portfolio highlights

Robeaute — Redesigning the future of neurosurgery by creating the new standard device that will provide surgeons with seamless access to delicate areas of the brain parenchyma and with real-time data.
Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
Sphingotec GmbH — Improving patient outcomes with innovative diagnostics for critical care: Actionable insights in real-time

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
Alesta Therapeutics — Alesta Therapeutics pioneers innovative small molecule therapies for rare diseases, including hypophosphatasia and Charcot-Marie-Tooth

As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The companyfocuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).

Investment focus

Biotechnology, Health Care, Medical
Series B, Series C, Series A
United States, Switzerland, China

Portfolio highlights

Upstream Bio — Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. Upstream Bio was founded in 2004 and was headquartered in the United States.
Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases

Climate protection through innovative technologies. The Technology Fund offers loan guarantees to Swiss companies whose novel products contribute to a sustainable reduction in greenhouse gas emissions

Investment focus

Information Technology, Software, Biotechnology
Debt Financing, Grant, Seed
Switzerland

Portfolio highlights

FGen — FGen is a Swiss start-up company founded 2011 in Basel as a spin-off from the Department of Biosystems Science and Engineering of the ETH Zurich. As a contract reasearch organization we collaborate with partners from Biotech, Life Sciences, and Pharma in order to establish efficient bioprocesses and to develop new biopharmaceuticals.
Calopad — Calopad, awarded by the Swiss Confederation, offers a unique and the most holistic solution in pain therapy and muscle regeneration. The therapeutic deep heat of 42 degrees solves any muscle pain, muscle tension, or muscle spasms of chronic patients in the long term and in a highly efficient way through new forms of therapy. With the associatedapp, Calopad brings the physiotherapist digitally into any user's home and enables personalized all-around care in real time - utterly independent of time and place. In the future, the modular design will make it possible to combine different therapies such as heat, cold, or light with just one device, opening up the possibility of new therapeutic successes.
Selfrag — SELFRAG AG is specialized in the development of high voltage pulse power products, plants and systems for selective fragmentation of solid materials.

TiVenture is a seed investment fund owned by the Fondazione Centenario Banca Stato that invests in early stage companies with innovative technologies and high growth potential, principally in southern Switzerland. TiVenture is actively looking and ready to support exceptional founders and entrepreneurs developing scalable products for the globalmarket. TiVenture has a diversified portfolio of companies and is mainly active in the life science, medical, high-tech and IT sectors.

Investment focus

Software, Analytics, Renewable Energy
Seed, Series A, Funding Round
Switzerland, Italy, United States

Portfolio highlights

Hoxell — Hoxell is an intuitive and easy-to-use integrated platform that digitizes and streamlines all hospitality operations.
Hive Power — Hive Power provides a SaaS platform to optimise your existing electrical distribution grid, both from the technical and economic points of view.
Gaia Turbine — Gaia Turbine SA - High-Performance Hydroelectric Turbine for micro and mini power plants

Swiss ICT Investor Club (SICTIC) connects smart money investors to Swiss seed and early-stage tech startups.

Investment focus

Software, Artificial Intelligence, Information Technology
Seed, Pre-Seed, Funding Round
Switzerland, Germany, United Kingdom

Portfolio highlights

Pelt8 — Pelt8 enables climate action through the platform with scalable processes and controls to collect sustainability-related data in an easy and traceable way.
Creaitor — Creaitor is the ultimate solution for content producers, offering a comprehensive suite of AI tools and integrated SEO features. Streamline your content creation process and optimize your online presence with our powerful platform.
Insurteam — Insurteam provides the benefits of its technology to all insurance companies that service the travel and leisure sector.

We are a leading early-stage investment platform. We are at the center of a global ecosystem that attracts and fuels the technical founders and product teams building the next wave of global businesses.

Investment focus

Software, Information Technology, Artificial Intelligence
Seed, Series A, Pre-Seed
United States, United Kingdom, France

Portfolio highlights

Deta — The cloud for doers and dreamers
AnySignal — AnySignal was developed to reimagine how RF capabilities are delivered for the most difficult tasks around the globe. offers complete solutions for modern aircraft, satellites, and national security that span communications, radar, navigation, and RF sensing. Current solutions are overpriced, unimaginative, and provide little end-to-end capability.To shift this paradigm, they are bringing the appropriate talent, procedures, and technologies together. They are developing communications systems for satellites, launchers, space stations, and aircraft. They provide full-stack connectivity solutions that include software modems, hardware for use in flight and on the ground, data management software, ground station integration software, and vehicle telemetry software.
Harbinger — Founded by veterans of Canoo and Faraday Future, Harbinger is an automotive company that develops EV platforms optimized for medium-duty trucks and delivery vans.

Primal Capital, an independent venture capital " incubator bait fund at ", served as the Associate than July 2012 Hiroshi was Sasaki is the venture capital fund that serves as the representative partner. Representative of Sasaki, the seed acceleration program "Incubate Camp" operated by Incubate bait fund is carried out a totalof four times of planning and management than in 2012, They have also engaged in support operations of portfolio companies. - See more at: https://www.crunchbase.com/organization/primal-capital#sthash.m2z1DCbt.dpuf

Investment focus

Information Technology, Software, Internet
Seed, Funding Round, Pre-Seed
Japan, Spain, Switzerland

Portfolio highlights

Degas — Degas develops solutions to improve the productivity of small-scale farmers in Africa.
RemitAid — RemitAid is a fintech company that operates an overseas payment platform for cross-border transactions between companies.
xCARE — xCARE specializes in the development and commercialization phases of the pharmaceutical and medical device industries.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

IonKraft — IonKraft can provide better performance at a lower cost while maintaining recyclability, they also promote material reduction and reuse and are commercializing the technology with funding from the German Federal Ministry for Economic Affairs and Energy (BMWi).
NovoLINC — NovoLINC is a pioneering startup that provides thermal interface solutions. It develops a distinctive system of nanostructured materials and a proprietary manufacturing process with the objective of transforming thermal management.
Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.

Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.

Investment focus

Biotechnology, Health Care, Software
Series B, Series A, Funding Round
France, United States, Spain

Portfolio highlights

Corti — Corti offers a digital assistant, augmenting medics in improving patient outcomes and internal performance.
Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
Stilla Technologies — Stilla Technologies is taking digital PCR to a whole new level with a unique 6-color target detection capability

A corporate venture investment company focussed on investing in mid to late stage clinical stage therapeutics development companies in North America and Europe

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Series B, Series A
United Kingdom, Switzerland, United States

Portfolio highlights

Amlo Biosciences — From ground-breaking research to revolutionary prognostics and diagnostics AMLo Biosciences is translating ground-breaking research in cancer biomarkers int ...
Acousia Therapeutics — Acousia Therapeutics GmbH is a privately held biotech company based in Tübingen, Germany. Acousia has experience and expertise in identifying and developing small molecule drug candidates for the treatment of hearing loss.Sensory hair cells are the key cells for hearing in the inner ear. Acousia`s approach will help to replace lost hair cells bycellular regeneration originating from supporting cells.ASpherecousia is developing drugs for local application, which will restore hearing in patients who have lost their hearing ability induced by various reasons, e.g. noise trauma, treatment with ototoxic drugs or sudden deafness. In addition, these therapies will have the potential to treat the age-related decrease in hearing capacity.
Spiral Therapeutics — Spiral Therapeutics is a clinical stage pharmaceutical company delivering novel therapies for hearing loss. Through the use proprietary therapeutics and drug delivery technologies, Spiral is building a pipeline of advanced therapies in a field with large unmet needs and no approved therapies. Spiral’s lead candidate, LPT99, reached the clinic inDecember 2018. Spiral was launched in early 2016 and is headquartered in Brisbane, CA.

The University of Zurich is one of the leading research universities in Europe and offers the widest range of degree programs in Switzerland.

Investment focus

Health Care, Life Science, Biotechnology
Series A
Switzerland

Portfolio highlights

MUVON Therapeutics — Muvon Therapeutics platform helps women with urinary incontinence and treats diseases based on skeletal muscle degradation, supporting them in their commitment to living a healthy life. The company's mode of contact is by mail, phone, and physical address.

EFI Lake Geneva Ventures is a seed and early-stage investment strategy based in Geneva, Switzerland. Founded in 2020, our mission is to foster innovation by investing at an early stage in fast-growing innovative Swiss companies in Technology, Life Sciences and Medtech.

Investment focus

Health Care, Medical, Life Science
Seed, Pre-Seed, Series B
Switzerland, Germany

Portfolio highlights

Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
FluoSphera — Fluosphera better predicts the effects of molecules through animal-free microphysiological systems, helping you to discover more efficient drugs with less adverse side effects.
Seprify — Enabling sustainable products

Privilege Ventures is the venture capital arm of Privilège Management and invest in seed and early stage companies. Geographical focus is Switzerland and the rest of Europe. Focus sectors are industrial-tech, med-tech, wearables and in general ICT.

Investment focus

Health Care, Hardware, Software
Seed, Series A, Funding Round
Switzerland, France

Portfolio highlights

Wyth — Wyth makes technologies that help humans create meaningful relationships by bringing emotions, stories and connections beyond the interface.
Smeetz — Smeetz is the future of a unified, data-driven and dynamic pricing-oriented commerce for attractions and cultural venues.
Avelo — Our mission is to save lives by bringing fast and actionable infectious disease diagnosis closer to the patient. Avelo's solution is a breath collection device. It works with existing molecular tests to detect multiple respiratory tract infections causing pneumonia

Recipharm Venture Fund is part of Recipharm AB.

Investment focus

Biotechnology, Medical, Health Care
Series A, Funding Round
Sweden, Switzerland

Portfolio highlights

NewBiologix — NewBiologix operates as a technology innovation company, develops a proprietary and breakthroughDNA integration platform for the advanced engineering of human and mammaliancell lines.
Cinclus Pharma — A Swedish pharma company bringing relief to the world with the clinical stage drug candidate linaprazan glurate for gastric acid related diseases.

Amboy Street Ventures focuses on sexual health and women’s health technology startups. Amboy Street Ventures was founded in 2021 and was headquartered in Los Angeles, USA.

Investment focus

Health Care, Women's, Biotechnology
Series A, Seed, Series B
United States, Sweden, Switzerland

Portfolio highlights

Alloy — Alloy is a telehealth company addressing the healthcare needs of women over 40.
Granata Bio — Granata Bio is a biopharma company focused on women's health and infertility. Our mission and focus is to create access for fertility patients by introducing new therapeutic solutions.
Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se

Heritage Bank

Investment focus

Biopharma, Life Science
Seed
Switzerland

Portfolio highlights

Lagosta — WHAT WE DO. At LAGOSTA, we take great care in sustainably farming the European spiny lobster, converting byproducts in unique highly valuable products and setting up a series of ecological programs. Accelerated depletion of wild stocks due to overfishing and

Medicxi is an investment firm that focuses on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series B, Seed
United States, United Kingdom, The Netherlands

Portfolio highlights

Rapt Therapeutics — RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selectivesmall molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The company’s lead oncology drug candidate, FLX475, reached the clinic in just two and a half years with its lead inflammation drug candidate, RPT193, also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development.
Vicebio — Vicebio is committed to employing the Molecular Clamp Technology to create vaccines against next-generation respiratory viruses. Vicebio is a biopharmaceutical business that creates innovative vaccinations to prevent potentially fatal respiratory viral infections.
Ottimo Pharma — Ottimo Pharma is a private biotechnology company dedicated to enhancing cancer treatment outcomes and minimizing the overall healthcare burden.

Renaissance is an investment foundation for pension funds investing in Swiss SMEs. It acts as a partner of the SMEs, participating in companies within the framework of succession planning or company outsourcing and thus promotes the Swiss SME landscape by maintaining and creating jobs.The firm was founded in 1997 and is headquartered in Lausanne,Vaud.

Investment focus

Medical, Software, Health Care
Series B, Series C, Seed
Switzerland

Portfolio highlights

Anergis — Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland.
GlassIG — It is an independent software vendor. Our aim is to provide market leading and cost effective Information Governance for everyone. At They are proud of our mission to serve and inspire our customers to establish and operate an effective Information Governance solution.
Beqom — beqom is a Total Compensation Management Software Solution focused exclusively on managing compensation & performance for HR & Sales.

Rhia Ventures invests in reproductive healthcare solutions that empower women.

Investment focus

Health Care, Biotechnology, Women's
Seed, Series A, Pre-Seed
United States, Canada, Israel

Portfolio highlights

Eli — Hormone testing redesigned so you can monitor anytime, anywhere.
Contraline — Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam isnon-hormonal, designed to last years, and easily reversible.
Twentyeight Health — Your birth control. Delivered to your door. Get a new or re-up existing prescriptions, free & fast deliveries and follow up messaging with doctors. $0 with insurance and starting at $16/pack without.

White Loop Capital is the first investment firm specialized in crypto-assets in France. Accompanying those who dare.

Investment focus

Finance, Software, Life Science
Seed, Pre-Seed, Funding Round
Switzerland

Portfolio highlights

Ondefy — Ondefy is building infrastructure that enables a simple access to decentralized finance. Integrate multiple DeFi services unders 1 line of code.
Usual — Usual Labs operates as a decentralized finance(DeFi) protocol.
LayerZero Labs — LayerZero Labs is a blockchain messaging protocol developer that allows decentralized applications build across multiple blockchains. The company is a User Application (UA) configurable on-chain endpoint that runs a ULN.

RH Capital a Rhia Ventures fund, is an impact-first venture capital firm that invests in early-stage startups with the potential to transform women's health and increase health equity.

Investment focus

Health Care, Biotechnology, Health Diagnostics
Funding Round
United States

Portfolio highlights

Novocuff — Novocuff is a medical device firm that aims to improve pregnancy outcomes and reduce preterm deliveries caused by PPROM and cervical shortening.
Ocon Healthcare — OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions.In addition to our flagshipproduct, the IUB™ Ballerine®, OCON healthcare is developing an innovative pipeline of products utilizing the IUB™ frame for indications such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas/fibroids, and infertility.
Seven Starling — Seven Starling offers comprehensive online care for postpartum mental health. Take the free assessment to get started.

Students run the whole VC operation and are supported by a strong network of mentors. S2S is organized as a cross-campus initiative (ETH Zurich, EPFL, HSG, UZH) that fosters collaboration between different existing entrepreneurial student organizations.

Investment focus

Health Care, Information Technology, Software
Pre-Seed, Funding Round, Convertible Note
Switzerland, Germany

Portfolio highlights

Rrreefs — Our mission is to regenerate degraded coral reefs at global scale - restoring rich marine biodiversity for a healthy ocean.
Yuon Control — Yuon Control offers an advanced and predictive heating control system designed to optimize heating networks. It makes an effective contribution to CO2 reduction.
Cotierra — Biochar made from agricultural residues in the tropics can become a gamechanger for farmers and climate change mitigation

Investors by industry

Artificial intelligence